Major grade 3 and 4 organ toxicities (NCIC scale) observed in 358 patients in the FL2000 study
| Grade 3-4 toxicities . | Induction (first 6 months of treatment) . | Consolidation (additional 12 months) . | ||
|---|---|---|---|---|
| Number (%) . | Number (%) . | |||
| CHVP+I . | R-CHVP+I . | CHVP+I . | R-CHVP+I . | |
| Neutrophil | 114 (62) | 103 (59) | 69 (38) | 11 (6)* |
| Hemoglobin | 9 (5) | 6 (3) | 4 (2) | 1 (1) |
| Platelets | 6 (3) | 5 (3) | 4 (2) | 2 (2) |
| Fever | 2 (1) | 2 (1) | 1 (1) | 0 (0) |
| Infection | 0 (0) | 4 (2) | 2 (1) | 2 (1) |
| Cardiac | 3 (2) | 2 (2) | 1 (1) | 0 (0) |
| Grade 3-4 toxicities . | Induction (first 6 months of treatment) . | Consolidation (additional 12 months) . | ||
|---|---|---|---|---|
| Number (%) . | Number (%) . | |||
| CHVP+I . | R-CHVP+I . | CHVP+I . | R-CHVP+I . | |
| Neutrophil | 114 (62) | 103 (59) | 69 (38) | 11 (6)* |
| Hemoglobin | 9 (5) | 6 (3) | 4 (2) | 1 (1) |
| Platelets | 6 (3) | 5 (3) | 4 (2) | 2 (2) |
| Fever | 2 (1) | 2 (1) | 1 (1) | 0 (0) |
| Infection | 0 (0) | 4 (2) | 2 (1) | 2 (1) |
| Cardiac | 3 (2) | 2 (2) | 1 (1) | 0 (0) |
No significant differences in terms of grade 3 or 4 toxicities were observed between the 2 treatment arms except for neutrophil toxicity.
P < .001.